Format

Send to

Choose Destination
Oncologist. 2012;17(2):274-8. doi: 10.1634/theoncologist.2011-0198. Epub 2012 Jan 26.

Characteristics of oral mucosal events related to bevacizumab treatment.

Author information

1
Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York 10022, USA.

Abstract

BACKGROUND:

Bevacizumab, a monoclonal antibody targeting a vascular endothelial growth factor (VEGF) protein, has been reported to induce mucosal toxicities. However, the clinical characteristics of these particular toxicities have not been well characterized. We aimed at providing a detailed clinical description of signs and symptoms limited to the tongue mucosa in patients treated with bevacizumab.

METHODS:

A retrospective review of medical records and clinical photographs was performed with specific attention to clinical presentation, evolution, associated symptoms, concomitant medications, and treatment methods.

RESULTS:

In total, four patients presented to the dermatology service with clinical findings characterized by multifocal, erythematous circinate and serpiginous erosions on the dorsal tongue surrounded by white hyperkeratotic rims that were temporally related to bevacizumab therapy. Associated increased sensitivity to spicy foods was frequently observed.

CONCLUSION:

These characteristic clinical findings are consistent with geographic tongue. However, large prospective evaluations are necessary to confirm this potential relationship. If bevacizumab is indeed associated with geographic tongue, increased awareness may result in improved reporting and characterization of this particular adverse event.

Comment in

PMID:
22282905
PMCID:
PMC3286177
DOI:
10.1634/theoncologist.2011-0198
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center